Search

Your search keyword '"Tang, Ling-Long"' showing total 29 results
Start Over Author "Tang, Ling-Long" Publisher wiley
29 results on '"Tang, Ling-Long"'

2. The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma

Author

Li, Xiao‐Min, primary, Zhang, Xiao‐Min, additional, Li, Jun‐Yan, additional, Jiang, Ning, additional, Chen, Lei, additional, Tang, Ling‐Long, additional, Mao, Yan‐Ping, additional, Li, Wen‐Fei, additional, Zhou, Guan‐Qun, additional, Li, Ying‐Qin, additional, Liu, Na, additional, Zhang, Yuan, additional, and Ma, Jun, additional

Published
2022
Full Text
View/download PDF

3. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma

Author

Tang, Ling‐Long, primary, Chen, Yu‐Pei, additional, Chen, Chuan‐Ben, additional, Chen, Ming‐Yuan, additional, Chen, Nian‐Yong, additional, Chen, Xiao‐Zhong, additional, Du, Xiao‐Jing, additional, Fang, Wen‐Feng, additional, Feng, Mei, additional, Gao, Jin, additional, Han, Fei, additional, He, Xia, additional, Hu, Chao‐Su, additional, Hu, De‐sheng, additional, Hu, Guang‐Yuan, additional, Jiang, Hao, additional, Jiang, Wei, additional, Jin, Feng, additional, Lang, Jin‐Yi, additional, Li, Jin‐Gao, additional, Lin, Shao‐Jun, additional, Liu, Xu, additional, Liu, Qiu‐Fang, additional, Ma, Lin, additional, Mai, Hai‐Qiang, additional, Qin, Ji‐Yong, additional, Shen, Liang‐Fang, additional, Sun, Ying, additional, Wang, Pei‐Guo, additional, Wang, Ren‐Sheng, additional, Wang, Ruo‐Zheng, additional, Wang, Xiao‐Shen, additional, Wang, Ying, additional, Wu, Hui, additional, Xia, Yun‐Fei, additional, Xiao, Shao‐Wen, additional, Yang, Kun‐Yu, additional, Yi, Jun‐Lin, additional, Zhu, Xiao‐Dong, additional, and Ma, Jun, additional

Published
2021
Full Text
View/download PDF

4. Evolving landscape and academic attitudes toward the controversies of global immuno‐oncology trials

Author

Xu, Cheng, primary, Zhang, Shu, additional, Zhang, Yuan, additional, Tang, Si‐Qi, additional, Fang, Xue‐Liang, additional, Zhu, Guang‐Li, additional, Peng, Liang, additional, Liu, Jin‐Qi, additional, Mao, Yan‐Ping, additional, Tang, Ling‐Long, additional, Liu, Qing, additional, Lin, Ai‐Hua, additional, Sun, Ying, additional, and Ma, Jun, additional

Published
2021
Full Text
View/download PDF

8. Thyroid dose‐volume thresholds for the risk of radiation‐related hypothyroidism in nasopharyngeal carcinoma treated with intensity‐modulated radiotherapy—A single‐institution study

Author

Huang, Cheng‐Long, primary, Tan, Hong‐Wen, additional, Guo, Rui, additional, Zhang, Yuan, additional, Peng, Hao, additional, Peng, Liang, additional, Lin, Ai‐Hua, additional, Mao, Yan‐Ping, additional, Sun, Ying, additional, Ma, Jun, additional, and Tang, Ling‐Long, additional

Published
2019
Full Text
View/download PDF

9. The development and external validation of simplified T category classification for nasopharyngeal carcinoma to improve the prognostic value in the intensity‐modulated radiotherapy era

Author

Tang, Ling‐Long, primary, Liang, Shao‐Bo, additional, Huang, Cheng‐Long, additional, Zhang, Fan, additional, Xu, Cheng, additional, Mao, Yan‐Ping, additional, Tian, Li, additional, Lin, Ai‐Hua, additional, Li, Li, additional, Sun, Ying, additional, and Ma, Jun, additional

Published
2019
Full Text
View/download PDF

10. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long‐term results of phase 3 randomized controlled trial

Author

Li, Wen‐Fei, primary, Chen, Nian‐Yong, additional, Zhang, Ning, additional, Hu, Guo‐Qing, additional, Xie, Fang‐Yun, additional, Sun, Yan, additional, Chen, Xiao‐Zhong, additional, Li, Jin‐Gao, additional, Zhu, Xiao‐Dong, additional, Hu, Chao‐Su, additional, Xu, Xiang‐Ying, additional, Chen, Yuan‐Yuan, additional, Hu, Wei‐Han, additional, Guo, Ling, additional, Mo, Hao‐Yuan, additional, Chen, Lei, additional, Mao, Yan‐Ping, additional, Sun, Rui, additional, Ai, Ping, additional, Liang, Shao‐Bo, additional, Long, Guo‐Xian, additional, Zheng, Bao‐Min, additional, Feng, Xing‐Lai, additional, Gong, Xiao‐Chang, additional, Li, Ling, additional, Shen, Chun‐Ying, additional, Xu, Jian‐Yu, additional, Guo, Ying, additional, Chen, Yu‐Ming, additional, Zhang, Fan, additional, Lin, Li, additional, Tang, Ling‐Long, additional, Liu, Meng‐Zhong, additional, Ma, Jun, additional, and Sun, Ying, additional

Published
2019
Full Text
View/download PDF

13. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma

Author

Guo, Rui, primary, Tang, Ling-Long, additional, Mao, Yan-Ping, additional, Du, Xiao-Jing, additional, Chen, Lei, additional, Zhang, Zi-Chen, additional, Liu, Li-Zhi, additional, Tian, Li, additional, Luo, Xiao-Tong, additional, Xie, Yu-Bin, additional, Ren, Jian, additional, Sun, Ying, additional, and Ma, Jun, additional

Published
2018
Full Text
View/download PDF

20. Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large‐scale, big‐data intelligence platform–based analysis from an endemic area

Author

Lv, Jia‐Wei, primary, Chen, Yu‐Pei, additional, Huang, Xiao‐Dan, additional, Zhou, Guan‐Qun, additional, Chen, Lei, additional, Li, Wen‐Fei, additional, Tang, Ling‐Long, additional, Mao, Yan‐Ping, additional, Guo, Ying, additional, Xu, Rui‐Hua, additional, Ma, Jun, additional, and Sun, Ying, additional

Published
2017
Full Text
View/download PDF

23. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma

Author

Liu, Na, primary, Cui, Rui-Xue, additional, Sun, Ying, additional, Guo, Rui, additional, Mao, Yan-Ping, additional, Tang, Ling-Long, additional, Jiang, Wei, additional, Liu, Xu, additional, Cheng, Yi-Kan, additional, He, Qing-Mei, additional, Cho, William C.S., additional, Liu, Li-Zhi, additional, Li, Li, additional, and Ma, Jun, additional

Published
2013
Full Text
View/download PDF

24. Prognostic value of chronic hepatitis B virus infection in patients with nasopharyngeal carcinoma: Analysis of 1301 patients from an endemic area in China

Author

Liu, Xu, primary, Li, Xing, additional, Jiang, Ning, additional, Lei, Ying, additional, Tang, Ling-Long, additional, Chen, Lei, additional, Zhou, Guan-Qun, additional, Sun, Ying, additional, Yue, Dan, additional, Guo, Rui, additional, Mao, Yan-Ping, additional, Li, Wen-Fei, additional, Liu, Li-Zhi, additional, Tian, Li, additional, Lin, Ai-Hua, additional, and Ma, Jun, additional

Published
2013
Full Text
View/download PDF

26. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of Ch

Author

Chen, Yong, primary, Sun, Ying, additional, Liang, Shao-Bo, additional, Zong, Jing-Feng, additional, Li, Wen-Fei, additional, Chen, Mo, additional, Chen, Lei, additional, Mao, Yan-Ping, additional, Tang, Ling-Long, additional, Guo, Ying, additional, Lin, Ai-Hua, additional, Liu, Meng-Zhong, additional, and Ma, Jun, additional

Published
2013
Full Text
View/download PDF

28. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.

Author

Guo R, Tang LL, Mao YP, Du XJ, Chen L, Zhang ZC, Liu LZ, Tian L, Luo XT, Xie YB, Ren J, Sun Y, and Ma J

Subjects
DNA, Viral radiation effects, Epstein-Barr Virus Infections radiotherapy, Female, Herpesvirus 4, Human radiation effects, Humans, Male, Nasopharyngeal Carcinoma radiotherapy, Nasopharyngeal Carcinoma virology, Nasopharyngeal Neoplasms radiotherapy, Nasopharyngeal Neoplasms virology, Neoplasm Staging, Prognosis, Prospective Studies, Radiotherapy, Intensity-Modulated, Retrospective Studies, Survival Analysis, Treatment Outcome, DNA, Viral blood, Epstein-Barr Virus Infections pathology, Herpesvirus 4, Human genetics, Nasopharyngeal Carcinoma pathology, Nasopharyngeal Neoplasms pathology
Abstract

Background: The prognosis of patients who have Epstein-Barr virus (EBV)-related nasopharyngeal carcinoma (NPC) in which the tumor tissues harbor EBV have a better prognosis than those without EBV-related NPC. Therefore, the eighth edition of the TNM staging system could be modified for EBV-related NPC by incorporating the measurement of plasma EBV DNA., Methods: In total, 979 patients with NPC who received intensity-modulated radiotherapy (IMRT) were retrospectively reviewed. Recursive partitioning analysis was conducted based on tumor (T) classification, lymph node (N) classification, and EBV DNA measurement to derive objectively the proposed stage groupings. The validity of the proposed stage groupings was confirmed in a prospective cohort of 550 consecutive patients who also received with IMRT., Results: The pretreatment plasma EBV DNA level was identified as a significant, negative prognostic factor for progression-free survival and overall survival in univariate analysis (all P < .001) and multivariate analysis (all P < .05). Recursive partitioning analysis of the primary cohort to incorporate EBV DNA generated the following proposed stage groupings: stage RI (T1N0), RIIA (T2-T3N0 or T1-T3N1, EBV DNA ≤2000 copies/mL), stage RIIB (T2-T3N0 or T1-T3N1, EBV DNA >2000 copies/mL; T1-T3N2, EBV DNA ≤2000 copies/mL), stage RIII (T1-T3N2, EBV DNA >2000 copies/mL; T4N0-N2), and stage RIVA (any T and N3). In the validation cohort, the 5-year progression-free survival rate was 100%, 87.9%, 76.7%, 68.7%, and 50.4% for proposed stage RI, RIIA, RIIB, RIII, and RIV NPC, respectively (P < .001). Compared with the eighth edition TNM stage groupings, the proposed stage groupings incorporating EBV DNA provided better hazard consistency, hazard discrimination, outcome prediction, and sample size balance., Conclusions: The proposed stage groupings have better prognostic performance than the eighth edition of the TNM staging system. EBV DNA titers should be included in the TNM staging system to assess patients who have EBV-related NPC., (© 2018 American Cancer Society.)

Published
2019
Full Text
View/download PDF

29. Prognostic value of chronic hepatitis B virus infection in patients with nasopharyngeal carcinoma: analysis of 1301 patients from an endemic area in China.

Author

Liu X, Li X, Jiang N, Lei Y, Tang LL, Chen L, Zhou GQ, Sun Y, Yue D, Guo R, Mao YP, Li WF, Liu LZ, Tian L, Lin AH, and Ma J

Subjects
Carcinoma, China epidemiology, Female, Humans, Incidence, Male, Middle Aged, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms mortality, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Treatment Outcome, Endemic Diseases, Hepatitis B, Chronic epidemiology, Nasopharyngeal Neoplasms epidemiology, Nasopharyngeal Neoplasms virology
Abstract

Background: The current study investigated the prevalence and prognostic value of chronic hepatitis B virus (HBV) infection in patients with nasopharyngeal carcinoma (NPC) from an area in southern China in which HBV and NPC are endemic., Methods: A total of 1301 patients with nonmetastatic, histologically proven NPC who were treated with radiotherapy or chemoradiotherapy were retrospectively reviewed., Results: In this series, 142 of the 1301 patients (10.9%) had chronic HBV infection (hepatitis B surface antigen [HBsAg] seropositive). The percentages of non-cancer-related deaths (15.0% vs 12.1%; P = .618) and severe hepatic adverse events (3.5% vs 0.9%; P = .145) were similar among patients with NPC with and without HBV infection. The 5-year overall survival (OS), progression-free survival (PFS), and locoregional recurrence-free survival (LRFS) rates for patients with NPC with or without HBV infection were 70.9% and 80.8% (P = .003), 63.7% and 73.0% (P = .016), and 81.7% and 88.2% (P = .035), respectively. Multivariate analysis identified chronic HBV infection in patients with NPC as an independent unfavorable prognostic factor for OS (hazards ratio [HR], 1.684; P = .003), PFS (HR, 1.451; P = .015), and LRFS (HR, 1.573; P = .048). Further analysis revealed that chronic HBV infection was an unfavorable, independent prognostic factor in patients with locoregionally advanced NPC, but not those with early-stage disease. In patients with stage III/IV NPC, HBsAg-positive patients had poorer OS (64.0% vs 77.2%; P = .003), PFS (56.2% vs 70.6%; P = .004), and LRFS (76.2% vs 88.3%; P = .002) compared with HBsAg-negative patients. On multivariate analysis, chronic HBV infection was found to be an independent adverse prognostic predictor for OS (HR, 1.734; P = .004), PFS (HR, 1.644; P = .003), and LRFS (HR, 2.108; P = .003) in patients with stage III/IV NPC., Conclusions: Chronic HBV infection is an independent adverse prognostic factor in patients with locoregionally advanced NPC., (© 2013 American Cancer Society.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results